Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms

Rancés Blanco; Enrique Rengifo; Charles E Rengifo; Mercedes Cedeño; Milagros Frómeta; Adriana Carr

doi:10.5402/2011/848909

Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms

ISRN Dermatol. 2011:2011:848909. doi: 10.5402/2011/848909. Epub 2011 Apr 10.

Authors

Rancés Blanco¹, Enrique Rengifo, Charles E Rengifo, Mercedes Cedeño, Milagros Frómeta, Adriana Carr

Affiliation

¹ Department of Quality Control, Center of Molecular Immunology, Havana 11600, Cuba.

Abstract

The evaluation of 14F7 Mab (anti-N-glycolyl GM3 ganglioside) immunorecognition in normal skin, cutaneous malignant melanoma (CMM), and in lymph node metastases (LNM) has been previously reported. In this work we extended the study to benign (BMN) and dysplastic (DMN) melanocytic nevi, basal (BCC), and squamous cell carcinoma (SCC). Immunohistochemical assays with 14F7 followed by a biotinylated link universal and streptavidin-AP in normal and pathological tissues were made. No reaction of 14F7 in normal skin (0/10) as well as a low reactivity in BMN (2/11) and DMN (1/7) was detected. A limited staining in BCC (2/13) and in SCC (4/8) was also evidenced, while 14F7 Mab were mostly reactive in CMM (28/28) and in LNM (6/7). These results suggest that 14F7 reactivity could be closely related with the more aggressive biological behavior of CMM and also support the use of NeuGcGM3 as target for both passive and active melanoma immunotherapy.